InvestorsHub Logo
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
Monroe1 Free
11/06/24 12:55 PM
Bullish
Bullish
profile icon
Monroe1 Free
11/06/24 12:20 PM
Bullish
Bullish
profile icon
Monksdream PremiumMember
09/02/24 3:20 PM
profile icon
bikaver Free
07/17/24 4:23 PM
profile icon
Pedro2004 Free
07/10/24 8:09 PM
profile icon
boston127 Free
07/09/24 9:18 PM
profile icon
gail PremiumMember
07/09/24 7:21 PM
profile icon
bikaver Free
07/09/24 7:15 PM
profile icon
gail PremiumMember
07/09/24 1:58 PM
profile icon
Pedro2004 Free
07/09/24 1:52 PM
profile icon
Pedro2004 Free
07/09/24 1:45 PM
profile icon
TrendTrade2016 Free
07/09/24 1:36 PM
profile icon
gail PremiumMember
07/09/24 1:36 PM
profile icon
Awl416 Free
07/09/24 1:34 PM
profile icon
TrendTrade2016 Free
07/09/24 1:32 PM
profile icon
TrendTrade2016 Free
07/09/24 1:14 PM
Bullish
Bullish
profile icon
gail PremiumMember
07/09/24 1:08 PM
Bullish
Bullish
profile icon
gail PremiumMember
07/09/24 1:07 PM
Bullish
Bullish
profile icon
gail PremiumMember
07/09/24 1:01 PM
profile icon
gail PremiumMember
07/09/24 12:30 PM
Bullish
Bullish
profile icon
gail PremiumMember
07/09/24 11:32 AM
Bullish
Bullish
profile icon
TrendTrade2016 Free
07/09/24 10:55 AM
profile icon
TrendTrade2016 Free
07/09/24 10:47 AM
profile icon
trader59 PremiumMember
07/09/24 10:16 AM
Bullish
Bullish
profile icon
TrendTrade2016 Free
07/09/24 9:58 AM
profile icon
TIMGZ Free
07/09/24 9:49 AM
profile icon
Awl416 Free
07/09/24 8:22 AM
profile icon
Monksdream PremiumMember
07/09/24 7:58 AM
profile icon
Awl416 Free
07/09/24 7:42 AM
profile icon
StockItOut Free
06/06/24 10:17 PM
profile icon
Monksdream PremiumMember
06/06/24 1:29 PM
profile icon
StockItOut Free
06/04/24 9:07 AM
profile icon
StockItOut Free
06/04/24 9:01 AM
profile icon
StockItOut Free
06/04/24 8:59 AM
profile icon
Zardiw PremiumMember
06/04/24 8:54 AM
profile icon
StockItOut Free
06/04/24 8:53 AM
profile icon
Zardiw PremiumMember
06/03/24 11:23 PM

Soligenix Inc (SNGX) RSS Feed

Followers
212
Posters
647
Posts (Today)
0
Posts (Total)
9814
Created
06/06/06
Type
Free
Moderators
Soligenix as of 9/09/2021: 
SNGX [NASD]
Soligenix, Inc.
Healthcare | Biotechnology | USA
https://finviz.com/quote.ashx?t=SNGX&ty=c&ta=1&p=d

[-chart]www.soligenix.com/wp-content/uploads/2019/05/T-cells.png[/chart]



[-chart]finviz.com/chart.ashx?t=SONN&ty=c&ta=1&p=d&s=l[/chart]
 

https://www.soligenix.com/
https://www.soligenix.com/about/
https://www.soligenix.com/pipeline-programs/
https://www.soligenix.com/clinical-trials/
https://www.soligenix.com/our-focus/
https://www.soligenix.com/partnering/
 

Soligenix, Inc. (Soligenix) is a late-stage biopharmaceutical company.
The Company is focused on developing and commercializing products to treat rare diseases.
The Company operates through two business segments:
Specialized BioTherapeutics and Public Health Solution. Soligenix’s Specialized BioTherapeutics business segment is developing
a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma (CTCL).
The Public Health Solutions business segment includes active development programs for RiVax,
its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic-resistant and emerging infectious disease.
CTCL is its innate defense regulator technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer.

 
 

Specialized BioTherapeutics Pipeline

Soligenix has expertise in the development of orphan and unmet medical need indications including preclinical, manufacturing, regulatory and clinical expertise.

 

 

Rising to the challenges of rare disease treatment
Soligenix is a late-stage biopharmaceutical company committed to developing and commercializing products to treat rare diseases where there is an unmet medical need.
<img alt="T-cell Image" class="initial loaded" data-cke-saved-src="https://www.soligenix.com/wp-content/uploads/2019/05/T-cells.png"; src="https://www.soligenix.com/wp-content/uploads/2019/05/T-cells.png"; style="animation:7s linear 0s 1 normal none running heroForegroundIn; border-style:none; box-sizing:inherit; color:inherit; display:block; font-family:object-fit: contain; height:549.438px; left:0px; max-width:100%; object-fit:contain; object-position:bottom right" ;="" opacity:1;="" position:relative;="" transform-origin:center="" center;="" transform:rotate(-45deg)="" translatex(0px);="" transition:opacity="" 0.5s="" ease="" 0s;="" visibility:visible;="" width:603.125px"="">
Scroll to next section

Specialized BioTherapeutics Pipeline

Soligenix has expertise in the development of orphan and unmet medical need indications including preclinical, manufacturing, regulatory and clinical expertise.

Preclinical Phase 1 Phase 2 Phase 3 Market
HyBryte™ for Cutaneous T-Cell Lymphoma (CTCL)
 
 
 
 
 
SGX942 for Oral Mucositis Treatment
 
 
 
 
 
SGX203 for Pediatric Crohn’s Disease
 
 
 
 
 
SGX201 for Radiation Enteritis Treatment
 
 
 
 
 

Orphan and/or Fast Track Designation

Denotes funding by NIH, BARDA, DTRA and/or FDA.

Public Health Solutions Pipeline

Soligenix has a number of Public Health programs, funded entirely by government grants and contracts, which focus on infectious disease and biodefense applications, including our most advanced vaccination program to prevent ricin poisoning.

Proof-of-Concept IND Phase 1 Phase 2/3 Market
RiVax® to Prevent Ricin Poisoning
 
 
 
 
 
SGX943 for Infectious Disease
 
 
 
 
 
ThermoVax®: Thermostabilized Vaccines for Global Use
 
 
 
 
 

Orphan and/or Fast Track Designation

Denotes funding by NIH, BARDA, DTRA and/or FDA.
Papers and chars with medical data

Corporate Presentation

May 10, 2021 Corporate Presentation
Papers and chars with medical data

Shareholder Update Letter

February 24, 2021 Shareholder Update Letter

The Latest

RESOURCES
EXTERNAL LINK

Recombinant protein subunit SARS-CoV-2 vaccines formulated with CoVaccine HT adjuvant induce broad, Th1 biased, humoral and cellular immune responses in mice 

COVID-19: Lai, C.Y., To, A., Wong, T.A.S., Lieberman, M.M., Clements, D.E., Senda, J.T., Ball, A.H., Pessaint, L., Andersen, H., Donini, O., Lehrer, A.T. Recombinant protein subunit SARS-CoV-2 vaccines formulated with CoVaccine HT adjuvant induce broad, Th1 biased, humoral and cellular immune responses in mice. 2021.

STAY ON TOP OF THE LATEST SOLIGENIX NEWS

SUBSCRIBE TO OUR NEWSLETTER
© Soligenix, 2021. All Rights Reserved.


 
Preclinical Phase 1 Phase 2 Phase 3 Market
HyBryte™ for Cutaneous T-Cell Lymphoma (CTCL) almost done [in phase 3]
 
 
 
 
 
SGX942 for Oral Mucositis Treatment   almost done [in phase 3]
 
 
 
 
 
SGX203 for Pediatric Crohn’s Disease   [phase 2 almost done]
 
 
 
 
 
SGX201 for Radiation Enteritis Treatment  [phase 1 going into phase 2]

ADDITION PIPELINE
 
Proof-of-Concept IND Phase 1 Phase 2/3 Market
RiVax® to Prevent Ricin Poisoning
 
 
 
 
 
SGX943 for Infectious Disease
 
 
 
 
 
ThermoVax®: Thermostabilized Vaccines for Global Use
 
 
 
 
 

Orphan and/or Fast Track Designation

Denotes funding by NIH, BARDA, DTRA and/or FDA.







 

PER  IHUB  MGMT 

02-07-2021
DISCLAIMER:  ONLY FOR MICK
https://investorshub.advfn.com/boards/profilea.aspx?user=1012
*The Board Monitor and herewithin , are not licensed brokers and assume NO responsibility for actions,
investments,decisions, or messages posted on this forum.
 
CONTENT ON THIS FORUM SHOULD NOT BE CONSIDERED ADVISORY NOR SOLICITATION 
AUTHORS MAY HAVE BUYS OR SELLS  WITH THE COMPANIES MENTIONED IN TRADING POSTERS SHOULD DUE DILIGENT BUYING OR SELLING.
ALL POSTING SHOULD BE CONSIDERED FOR INFORMATION ONLY. WE DO NOT RECOMMEND ANYONE BUY OR SELL ANY SECURITIES POSTED HEREWITHIN.

ANY trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.
Any


 








 
Volume:
Day Range:
Last Trade Time:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
New Post